230 likes | 1.13k Views
Division of Pharmaceutical Analysis. Lucinda F. Buhse, Ph.D., Director. Research in support of the Critical Path Dimensions Ensuring Safety Demonstrating Medical Utility Industrialization Process. Division of Pharmaceutical Analysis Critical Path Initiatives.
E N D
Division of Pharmaceutical Analysis Lucinda F. Buhse, Ph.D., Director Research in support of the Critical Path Dimensions Ensuring Safety Demonstrating Medical Utility Industrialization Process
Division of Pharmaceutical AnalysisCritical Path Initiatives • Characterize Novel Dosage Forms/ Complex Drug Substances • Measurement and ID of Micro and Nanoparticles • Establish Appropriate Surrogate Measurements Techniques • Drug Authenticity and Anti-counterfeiting Techniques • Process Analytical Technologies for Manufacturing • Computational Chemistry (Chemometrics)
Characterization of Novel Dosage Forms/ Complex Drug Substances Examples: • Liposomes –characterization after chemical and physical changes • Transdermals – physical characterization of adhesive strength • Conjugated Estrogens – improvement of LCMS comparison method • Protein Products -Detection of Aggregation and Degradation Regulatory Accomplishments: • Input into Conjugated Estrogens Guidance
Monitoring Liposomal Drug Products (LDPs) Under Manufacturing Stress Conditions LDPs (PEGylated Doxil ®, Conventional DaunoXome®) Stress Conditions Thermal Oxidative Acid and Base Light Sonication Detergent Analytical methods for Monitoring quality Drug Substance (HPLC-UV) Encapsulation Efficiency (fluorescence) Lipid Composition (HPLC-ELS) Particle Size Zeta Potential
Several sizes of patches, types of drug delivery, application periods, and shapes. Transdermal Drug Delivery Systems: Adhesive Strength Example of drug-in-adhesive Example of reservoir Test method development variables and constants: Test panel Rolls Rolling time Test panel cleaning Angle of pull Pull speed Dwell time Environment
Measurement and ID of Micro and Nanoparticles Examples: • Sunscreens – evaluation of particle size in the formulation • Nasal Sprays • evaluation of Raman Microimaging for particle sizing of active pharmaceutical ingredient • evaluation of Andersen Cascade Impactor configuration for use in assessing the distribution of fine particles Regulatory Accomplishments: • Input into Nasal Spray BA/BE Guidance • Development of compendial method for cyclosporine particle size
Measuring API Particle Size in the Presence of Particulate Excipients
Establishment of Appropriate Surrogate Measurement Techniques Example: • Mefloquine HCl – evaluation of polymorphs of API with respect to BA of finished dosage form • Megestrol Acetate – evaluation of dissolution media to detect BE/BA differences • Evaluation of variability in Dissolution testing – search for an alternative technique to establish BE/BA Regulatory Accomplishments: • Input into resolution of prophylaxis failure of military use product • Input into resolution of generic manufacturer equivalency challenge
Dissolution: Less variability is needed • The current USP 10-mg Prednisone Calibrator Tablets exhibit slower dissolution over time • Acceptance limits are so large, that improper mechanical calibration may not be detected • Differences in product testing can often be traced to improper mechanical calibration and/or degassing
Drug Authenticity and Anti-counterfeiting Techniques Example: • Assessment of technologies for detection of counterfeit (IRMS, NIR, TGA, Terahertz) Regulatory Accomplishments: • Quality of foreign Active Pharmaceutical Ingredients program • Foreign Internet Sample Studies
IRMS- Isotope Ratio Mass Spectrometry IRMS can provide the source of active pharmaceutical ingredients (APIs). In the bivariate isotope ratio graph shown, the typical clustering of the data is consistent with manufacturer-based isotopic provenance.
Process Analytical Technologies for Manufacturing Examples: • Assessment of technologies for PAT (Terahertz, NIR) • Effect of coating composition and thickness on PAT measurements • Effect of excipient and excipient/drug interaction
Terahertz Absorption Spectra Partial Least Squares Fit THz Predicted Content (mg) Absorbance Content (mg) by NIR PLS Calibration from HPLC Energy (5 - 45cm-1) • Non-Destructive and Penetrating • Imaging of Biological Tissue • On-Line or At-Line Quality Control including whole tablet imaging Terahertz Spectrometry Acetaminophen tablet content: 65 – 135 mg scanned by NIR and Terahertz Absorbance.
Computational Chemistry (Chemometrics) Examples: • Understanding chemometric software packages • Understanding limitations and benefits of multivariate techniques
Uncoated Acetaminophen tablets in 9 dosage levels 65 – 135mg. Critical Path - Chemometrics Tablet Reflectance – full range Tablet Transmittance – limited spectral range Data Range: 4000 – 10000cm-1 Data Range: 8600 – 10000cm-1 Reflectance Transmittance Near Infrared Reflectance and Transmittance of formulated tablets Multivariate models in PAT – Partial Least Squares (PLS) analysis Energy (cm-1) Energy (cm-1) PLS – Mean Centered, 2nd Derivative, 3 Factors PLS – Mean Centered, Direct Spectra, 3 Factors Calculated Content Calculated Content Content Measured by HPLC Content Measured by HPLC
Division of Pharmaceutical AnalysisSt. Louis, Mo. and White Oak, Md.